Tags

Type your tag names separated by a space and hit enter

[Orodental management in patients with malignant hematologic diseases who are waiting for bone marrow transplantation].
Minerva Stomatol. 1999 Dec; 48(12):615-9.MS

Abstract

BACKGROUND

This study aims to identify the main oral lesions caused by the use of chemotherapeutic agents pre- and post-transplant in malignant hemopathologies and to highlight the importance of dental prevention during this treatment in order to reduce and, if possible, avoid the resulting local and systemic complications.

METHODS

Twenty-five patients were controlled, monitored and prepared to undergo the necessary chemo- and radiotherapy, as well as bone marrow transplantation in the majority of cases under the best possible oral conditions.

RESULTS

The most commonly detected secondary lesions were reactions to cyclophosphamide and/or methotrexate. In general, this mucositis appeared 5-7 days after treatment and continued for 1-2 weeks before regressing without residue. Another post-radiotherapeutic complication observed was xerostomy.

CONCLUSIONS

Lastly, it is important to underline that patients receiving correct dental infection preventive treatment showed fewer tertiary lesions than those who did not undergo the same procedure.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

ita

PubMed ID

10822714

Citation

Bocca, M, et al. "[Orodental Management in Patients With Malignant Hematologic Diseases Who Are Waiting for Bone Marrow Transplantation]." Minerva Stomatologica, vol. 48, no. 12, 1999, pp. 615-9.
Bocca M, Coscia D, Bottalico L, et al. [Orodental management in patients with malignant hematologic diseases who are waiting for bone marrow transplantation]. Minerva Stomatol. 1999;48(12):615-9.
Bocca, M., Coscia, D., Bottalico, L., & De Stefano, R. (1999). [Orodental management in patients with malignant hematologic diseases who are waiting for bone marrow transplantation]. Minerva Stomatologica, 48(12), 615-9.
Bocca M, et al. [Orodental Management in Patients With Malignant Hematologic Diseases Who Are Waiting for Bone Marrow Transplantation]. Minerva Stomatol. 1999;48(12):615-9. PubMed PMID: 10822714.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Orodental management in patients with malignant hematologic diseases who are waiting for bone marrow transplantation]. AU - Bocca,M, AU - Coscia,D, AU - Bottalico,L, AU - De Stefano,R, PY - 2000/5/24/pubmed PY - 2000/6/10/medline PY - 2000/5/24/entrez SP - 615 EP - 9 JF - Minerva stomatologica JO - Minerva Stomatol VL - 48 IS - 12 N2 - BACKGROUND: This study aims to identify the main oral lesions caused by the use of chemotherapeutic agents pre- and post-transplant in malignant hemopathologies and to highlight the importance of dental prevention during this treatment in order to reduce and, if possible, avoid the resulting local and systemic complications. METHODS: Twenty-five patients were controlled, monitored and prepared to undergo the necessary chemo- and radiotherapy, as well as bone marrow transplantation in the majority of cases under the best possible oral conditions. RESULTS: The most commonly detected secondary lesions were reactions to cyclophosphamide and/or methotrexate. In general, this mucositis appeared 5-7 days after treatment and continued for 1-2 weeks before regressing without residue. Another post-radiotherapeutic complication observed was xerostomy. CONCLUSIONS: Lastly, it is important to underline that patients receiving correct dental infection preventive treatment showed fewer tertiary lesions than those who did not undergo the same procedure. SN - 0026-4970 UR - https://www.unboundmedicine.com/medline/citation/10822714/[Orodental_management_in_patients_with_malignant_hematologic_diseases_who_are_waiting_for_bone_marrow_transplantation]_ L2 - http://www.diseaseinfosearch.org/result/7171 DB - PRIME DP - Unbound Medicine ER -